B7-33

B7-33 — frequently asked questions

• What is B7-33?

  B7-33 is a single B-chain derivative peptide analogue of human relaxin-2 (H2 relaxin) that acts as a functionally selective relaxin family peptide receptor 1 (RXFP1) agonist. It was developed to replicate the cardiovascular and anti-fibrotic benefits of relaxin while offering improved stability and reduced complexity compared to the full two-chain relaxin hormone. B7-33 has demonstrated vasoprotective, anti-fibrotic, and cardioprotective properties in preclinical research.

• What is the half-life of B7-33?

  B7-33 has an approximate half-life of Extended compared to native relaxin-2, with lipidated derivatives showing further improved stability. The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.

• How is B7-33 administered?

  B7-33 is typically delivered via subcutaneous injection. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.

• How does B7-33 work?

  B7-33 selectively binds to and activates the relaxin family peptide receptor 1 (RXFP1), triggering intracellular signaling cascades that promote vasodilation, inhibit fibroblast activation and collagen deposition, and enhance extracellular matrix remodeling. Unlike full relaxin, B7-33 consists only of the B-chain component, which maintains receptor activation while demonstrating improved serum stability. The peptide reduces transforming growth factor-beta (TGF-β) signaling and inflammatory pathways involved in pathological fibrosis.

• What are the researched benefits of B7-33?

  Studied benefits of B7-33 include: Reduces cardiac fibrosis and adverse remodeling following myocardial infarction, Demonstrates anti-fibrotic effects in renal and other tissue fibrosis models, Replicates vasoprotective functions including improved endothelial function, Reduces fibrotic encapsulation of implanted materials and medical devices, Shows improved serum stability compared to native relaxin-2, Attenuates pathological cardiac remodeling while preserving function, Promotes extracellular matrix degradation and tissue remodeling. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.

• What are the side effects of B7-33?

  Reported side effects of B7-33 include: Limited human safety data currently available, Potential hypotensive effects due to vasodilatory activity, Theoretical risk of excessive matrix degradation with chronic use, Safety profile in pregnancy and reproductive function not established, Long-term cardiovascular effects in humans require further study. Always discuss potential side effects with a licensed healthcare provider before using any research peptide.